Barricaid

Greg Lambrecht, whose firsthand experience with his mother’s recurrent disc herniations inspired him to search for a better solution.

The page offers 1.0 CME credit hour and features Brandon Strenge, MD, and Benjamin J. Kirchner, PA-C, discussing use of Barricaid for recurrent herniation after discectomy.

Barricaid Annular Closure Device is designed to prevent repeat herniation in patients undergoing lumbar discectomy surgery to treat sciatic pain.

Annular repair and the field of disc biology are named one of the next big trends in the spine. Barricaid is designed to close large annular holes.

Annular closure and Barricaid for herniated disc patients feature in two articles in recent issues by IJSS, the International Journal of Spine Surgery.

MDDI (Medical Device and Diagnostic Industry) included Barricaid among its top MedTech companies to watch in 2020.

Hayes published a Health Technology Assessment of Barricaid on June 23, 2021, complementing an earlier positive assessment by ECRI. The assessment states that Barricaid is supported by clinical and economic evidence.

Barricaid was selected as a case study in an evaluation of evidence strength for Health Technology Assessments, citing clinical outcomes, health economics, and level 1 RCT data.

The company aims to reduce needless suffering by ensuring Barricaid is accessible to patients and surgeons.

The lower-back procedure uses a metal implant — commonly called a Barricaid device— to lower the chances of disk reherniation in patients who have already herniated a disk.

Discectomy surgery is performed approximately 350,000 to 480,000 discectomies per year in the United States. Here is news on Barricaid following discectomy.

Barricaid careers - impactful opportunities to join a fast-growing commercial team of a Massachusetts-based spine/medtech startup.

Intrinsic Therapeutics provides health economics and reimbursement resources for Barricaid, including guides and support for procedure coding, pre-authorization, benefit verification, and claims denials.

Barricaid board of directors is elected group that represents shareholders. The board meets at regular intervals to set policies for corporate management.

Intrinsic Therapeutics announced the appointment of Cary Hagan as President and Chief Executive Officer. Hagan has more than 20 years of experience in the orthopedic implant field, including product development, commercialization, and global marketing strategy.

Intrinsic Therapeutics has been recognized as a Top 20 MedTech company to watch. Barricaid Management is detailed here in all key areas of operations.

The page provides a contact form for inquiries about Barricaid at Intrinsic Therapeutics.

The page presents clinical evidence about Barricaid, including topics such as clinical need, safety data, and outcomes after discectomy.

Barricaid helps herniated disc surgery patients by reducing the risk of reherniation and reoperation, offering a breakthrough solution for recovery.